CorMedix Q1 Earnings Call Highlights
CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments. Chairman and Chi
MarketBeat ·